CLINICAL PIPELINE

Breakthrough Molecules, Breakthrough Care.

Our comprehensive pipeline spans from natural compounds to novel synthetic entities. Cubed is advancing a dual-track drug pipeline for high-impact psychiatric indications, with a long-term strategy to enter the neurodegenerative disease space.
After establishing a regulatory and commercial foothold in psychiatric indications, Cubed will pursue neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, and Traumatic Brain Injury (TBI). Initial entry will focus on mood and anxiety symptoms in these populations, where endpoints are validated, before exploring disease-modifying potential. Trials can be repeated for Generalized Anxiety Disorder (GAD), Major Depression & PTSD.

This staged approach mitigates the higher regulatory and trial complexity inherent in neurodegeneration in older patients while leveraging early psychiatric success to build clinical, CMC, and investor credibility.

Partners